CSA
HRTX icon

Cornerstone Select Advisors’s Heron Therapeutics HRTX Stock Holding History

Cornerstone Select Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.1K Sell
39,964
-19,450
-33% -$15.6K 0.01% 149
2026
Q1 		$47.5K Buy
59,414
+1,344
+2% +$1.56K 0.03% 124
2025
Q4 		$75.5K Sell
58,070
-1,000
-2% -$1.24K 0.05% 117
2025
Q3 		$74.4K Buy
59,070
+9,400
+19% +$14.9K 0.05% 110
2025
Q2 		$103K Sell
49,670
-185
-0.4% -$378 0.09% 110
2025
Q1 		$110K Sell
49,855
-900
-2% -$1.75K 0.1% 111
2024
Q4 		$77.7K Buy
+50,755
New +$82.3K 0.07% 111

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Cornerstone Select Advisors's HRTX Position: Q2 2026 in Review

Cornerstone Select Advisors reduced its Heron Therapeutics (HRTX) stake by 33% in Q2 2026, selling an estimated $15.6K and leaving 39,964 shares worth $17.1K. The position accounts for 0.01% of the portfolio, ranked #149.

Cornerstone Select Advisors first reported a position in HRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $110K in Q1 2025. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Cornerstone Select Advisors held 39,964 shares of Heron Therapeutics worth $17.1K as of Q2 2026.
  • Cornerstone Select Advisors sold 19,450 Heron Therapeutics shares in Q2 2026, an estimated $15.6K.
  • Heron Therapeutics made up 0.01% of Cornerstone Select Advisors's portfolio in Q2 2026, its #149 holding.
  • Cornerstone Select Advisors first reported a position in Heron Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Cornerstone Select Advisors's Heron Therapeutics position peaked at $110K in Q1 2025.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Cornerstone Select Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.